|
|
|
|
LEADER |
01755nam a2200241Ia 4500 |
001 |
10-3390-jcm11030592 |
008 |
220420s2022 CNT 000 0 und d |
020 |
|
|
|a 20770383 (ISSN)
|
245 |
1 |
0 |
|a Cell Death in AMD: The Rationale for Targeting Fas
|
260 |
|
0 |
|b MDPI
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.3390/jcm11030592
|
520 |
3 |
|
|a Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the developed world. While great advances have been made in the treatment of the neovascular (“wet”) form of the disease, there is still a significant need for therapies that prevent the vision loss associated with the advanced forms of dry, atrophic AMD. In this atrophic form, retinal pigment epithelial (RPE) and photoreceptor cell death is the ultimate cause of vision loss. In this review, we summarize the cell death pathways and their relation to RPE and retinal cell death in AMD. We review the data that support targeting programmed cell death through inhibition of the Fas receptor as a novel approach to preserve these structures and that this effect results from inhibiting both canonical death pathway activation and reducing the associated inflammatory response. These data lay the groundwork for current clinical strategies targeting the Fas pathway in this devastating disease. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
|
650 |
0 |
4 |
|a Apoptosis
|
650 |
0 |
4 |
|a Fas
|
650 |
0 |
4 |
|a Macular degeneration
|
650 |
0 |
4 |
|a Necroptosis
|
700 |
1 |
0 |
|a Cano, M.
|e author
|
700 |
1 |
0 |
|a Choi, J.J.
|e author
|
700 |
1 |
0 |
|a Gregory-Ksander, M.S.
|e author
|
700 |
1 |
0 |
|a Handa, J.T.
|e author
|
700 |
1 |
0 |
|a Kocab, A.J.
|e author
|
700 |
1 |
0 |
|a Zacks, D.N.
|e author
|
773 |
|
|
|t Journal of Clinical Medicine
|